Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| OCULAR THERAPEUTIX, INCOCUL · Entity 273 | Sr. VP Reg. Affairs & Quality | January 02, 2019 | January 04, 2019 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
OCULAR THERAPEUTIX, INC
Report date January 02, 2019 · Filed January 04, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.10 · Expires 2029-01-01 | Direct | 180,000 |
Reported balance
After 2019-01-02 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2019-01-02 · Grant · Acquired 180,000 · Balance 180,000 F1: Vests over four years, vesting 1/48 monthly beginning on the one-month anniversary of the date of grant. |
Filing footnotes · ownership attribution and instrument terms
F1: Vests over four years, vesting 1/48 monthly beginning on the one-month anniversary of the date of grant.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
ARIAD PHARMACEUTICALS INC
Report date February 16, 2017 · Filed February 16, 2017
Section 16 reporting ended · disclosed 2017-02-16. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2017-02-16 transaction · row 1
1 source rowRow 1 · 2017-02-16 · Disposition to issuer · Disposed 126,352 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger, dated as of January 8, 2017 (the "Merger Agreement"), between the Company, Takeda Pharmaceutical Company Limited ("Takeda") and Kiku Merger Co., Inc. ("Purchaser"), on February 16, 2017, Merger Sub was merged with and into the Company, with the Company continuing as the surviving corporation and a wholly owned subsidiary of Parent (the "Merger"). Pursuant to the Merger Agreement, at the effective time of the Merger, each share of common stock, par value $0.001 per share, of the Company (each, a "Share") was converted into the right to receive $24.00 in cash. |
| Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $15.05 | Direct | 0 |
Reported balance
After 2017-02-16 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2017-02-16 · Disposition to issuer · Disposed 38,000 · Balance 0 F2: Pursuant to the Merger Agreement, each option outstanding immediately prior to the consummation of the tender offer by Takeda and Purchaser to acquire all the outstanding Shares for $24.00 in cash (the "Offer"), whether vested or unvested, automatically became fully vested and was canceled as of immediately prior to, and contingent upon, the consummation of the Offer in exchange for the right to receive a lump-sum cash payment in the amount of the Option Consideration, if any, less any required withholding taxes, with respect to such Option. "Option Consideration" means, with respect to any Option, an amount equal to the product of (i) the number of Shares issuable under such Option multiplied by (ii) the excess of (x) $24.00 over (y) the exercise price payable in respect of each Share issuable under such Option; provided, however, that the Option Consideration for each Option with an exercise price equal to or greater than $24.00 shall be $0. |
| Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $20.89 | Direct | 0 |
Reported balance
After 2017-02-16 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2017-02-16 · Disposition to issuer · Disposed 48,000 · Balance 0 F2: Pursuant to the Merger Agreement, each option outstanding immediately prior to the consummation of the tender offer by Takeda and Purchaser to acquire all the outstanding Shares for $24.00 in cash (the "Offer"), whether vested or unvested, automatically became fully vested and was canceled as of immediately prior to, and contingent upon, the consummation of the Offer in exchange for the right to receive a lump-sum cash payment in the amount of the Option Consideration, if any, less any required withholding taxes, with respect to such Option. "Option Consideration" means, with respect to any Option, an amount equal to the product of (i) the number of Shares issuable under such Option multiplied by (ii) the excess of (x) $24.00 over (y) the exercise price payable in respect of each Share issuable under such Option; provided, however, that the Option Consideration for each Option with an exercise price equal to or greater than $24.00 shall be $0. |
| Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.51 | Direct | 0 |
Reported balance
After 2017-02-16 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2017-02-16 · Disposition to issuer · Disposed 60,000 · Balance 0 F2: Pursuant to the Merger Agreement, each option outstanding immediately prior to the consummation of the tender offer by Takeda and Purchaser to acquire all the outstanding Shares for $24.00 in cash (the "Offer"), whether vested or unvested, automatically became fully vested and was canceled as of immediately prior to, and contingent upon, the consummation of the Offer in exchange for the right to receive a lump-sum cash payment in the amount of the Option Consideration, if any, less any required withholding taxes, with respect to such Option. "Option Consideration" means, with respect to any Option, an amount equal to the product of (i) the number of Shares issuable under such Option multiplied by (ii) the excess of (x) $24.00 over (y) the exercise price payable in respect of each Share issuable under such Option; provided, however, that the Option Consideration for each Option with an exercise price equal to or greater than $24.00 shall be $0. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 0 |
Reported balance
After 2017-02-16 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2017-02-16 · Disposition to issuer · Disposed 52,666 · Balance 0 F3: Each restricted stock unit ("RSU") represents a right to receive one Share. Pursuant to the Merger Agreement, each RSU outstanding immediately prior to the consummation of the Offer automatically and without any required action on the part of its holder became fully vested and was converted immediately prior to, and contingent upon, the consummation of the Offer into a vested right to receive a lump-sum cash payment in an amount equal to $24.00 for each Share underlying the RSU, less any required withholding taxes. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 0 |
Reported balance
After 2017-02-16 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2017-02-16 · Disposition to issuer · Disposed 3,439 · Balance 0 F4: Pursuant to the Merger Agreement, each RSU outstanding immediately prior to the consummation of the Offer automatically and without any required action on the part of its holder shall be converted into the right to receive an amount in cash equal to $24.00 for each Share underlying the RSUs (the aggregate amount, the "RSU Payment"). Subject to the terms of the award agreement, the RSU Payment will generally be payable (without any crediting of interest for the period from the consummation of the Offer through the date of payment) in three annual installments with each such installment paid on the date that the RSUs corresponding to such installment would have otherwise vested in accordance with the terms of the award, less any required withholding taxes. |
Filing footnotes · ownership attribution and instrument terms
F1: Pursuant to the Agreement and Plan of Merger, dated as of January 8, 2017 (the "Merger Agreement"), between the Company, Takeda Pharmaceutical Company Limited ("Takeda") and Kiku Merger Co., Inc. ("Purchaser"), on February 16, 2017, Merger Sub was merged with and into the Company, with the Company continuing as the surviving corporation and a wholly owned subsidiary of Parent (the "Merger"). Pursuant to the Merger Agreement, at the effective time of the Merger, each share of common stock, par value $0.001 per share, of the Company (each, a "Share") was converted into the right to receive $24.00 in cash.
F2: Pursuant to the Merger Agreement, each option outstanding immediately prior to the consummation of the tender offer by Takeda and Purchaser to acquire all the outstanding Shares for $24.00 in cash (the "Offer"), whether vested or unvested, automatically became fully vested and was canceled as of immediately prior to, and contingent upon, the consummation of the Offer in exchange for the right to receive a lump-sum cash payment in the amount of the Option Consideration, if any, less any required withholding taxes, with respect to such Option. "Option Consideration" means, with respect to any Option, an amount equal to the product of (i) the number of Shares issuable under such Option multiplied by (ii) the excess of (x) $24.00 over (y) the exercise price payable in respect of each Share issuable under such Option; provided, however, that the Option Consideration for each Option with an exercise price equal to or greater than $24.00 shall be $0.
F3: Each restricted stock unit ("RSU") represents a right to receive one Share. Pursuant to the Merger Agreement, each RSU outstanding immediately prior to the consummation of the Offer automatically and without any required action on the part of its holder became fully vested and was converted immediately prior to, and contingent upon, the consummation of the Offer into a vested right to receive a lump-sum cash payment in an amount equal to $24.00 for each Share underlying the RSU, less any required withholding taxes.
F4: Pursuant to the Merger Agreement, each RSU outstanding immediately prior to the consummation of the Offer automatically and without any required action on the part of its holder shall be converted into the right to receive an amount in cash equal to $24.00 for each Share underlying the RSUs (the aggregate amount, the "RSU Payment"). Subject to the terms of the award agreement, the RSU Payment will generally be payable (without any crediting of interest for the period from the consummation of the Offer through the date of payment) in three annual installments with each such installment paid on the date that the RSUs corresponding to such installment would have otherwise vested in accordance with the terms of the award, less any required withholding taxes.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 02, 2019 Filed Jan 4, 2019 18:29 UTC | OCULAR THERAPEUTIX, INC OCUL · Entity 273 | GrantStock Option (Right to Buy) · Derivative | 180,000 | $0.00 Strike: $4.10 | $0.00 |
DisclosureSEC source: 0001104659-19-000894 · a4.xml · derivative · entry 1 Bollag Daniel M · CIK 0001461612 · Sr. VP Reg. Affairs & Quality 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 180,000 Underlying: Common Stock · 180,000 shares Expires 2029-01-01 F1 · derivative.exercise_date: Vests over four years, vesting 1/48 monthly beginning on the one-month anniversary of the date of grant. Read SEC document |
| December 06, 2018 Filed Dec 10, 2018 16:15 UTC | OCULAR THERAPEUTIX, INC OCUL · Entity 273 | PurchaseCommon Stock | 17,400 | $5.76 | $100,224.00 |
DisclosureSEC source: 0001104659-18-072100 · a4.xml · nonDerivative · entry 1 Bollag Daniel M · CIK 0001461612 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,100 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $5.75 to $5.79, inclusive. The reporting person undertakes to provide to Ocular Therapeutix, Inc., any security holder of Ocular Therapeutix, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (1) to this Form 4. Read SEC document |
| January 31, 2018 Filed Feb 2, 2018 16:35 UTC | OCULAR THERAPEUTIX, INC OCUL · Entity 273 | GrantStock Option (Right to Buy) · Derivative | 51,100 | $0.00 Strike: $5.47 | $0.00 |
DisclosureSEC source: 0001104659-18-006262 · a4.xml · derivative · entry 1 Bollag Daniel M · CIK 0001461612 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 51,100 Underlying: Common Stock · 51,100 shares Expires 2028-01-30 F1 · derivative.exercise_date: Vests over four years, vesting 1/48 monthly beginning on the one-month anniversary of the date of grant. Read SEC document |
| December 06, 2017 Filed Dec 8, 2017 16:26 UTC | OCULAR THERAPEUTIX, INC OCUL · Entity 273 | PurchaseCommon Stock | 24,700 | $3.93 | $97,071.00 |
DisclosureSEC source: 0001104659-17-072535 · a4.xml · nonDerivative · entry 1 Bollag Daniel M · CIK 0001461612 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,700 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $3.89 to $4.03, inclusive. The reporting person undertakes to provide to Ocular Therapeutix, Inc., any security holder of Ocular Therapeutix, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (1) to this Form 4. Read SEC document |
| August 07, 2017 Filed Aug 8, 2017 18:02 UTC | OCULAR THERAPEUTIX, INC OCUL · Entity 273 | GrantStock Option (Right to Buy) · Derivative | 110,000 | $0.00 Strike: $6.04 | $0.00 |
DisclosureSEC source: 0001104659-17-050339 · a4.xml · derivative · entry 1 Bollag Daniel M · CIK 0001461612 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 110,000 Underlying: Common Stock · 110,000 shares Expires 2027-08-06 F1 · derivative.exercise_date: Vests over four years, with 25% of the shares underlying the option vesting on the one-year anniversary of the grant date and 2.0833% of the shares vesting monthly thereafter. Read SEC document |
| February 16, 2017 Filed Feb 16, 2017 14:15 UTC | ARIAD PHARMACEUTICALS INC ARIA · Entity 134569 | Disposition to issuerRestricted Stock Units · Derivative | 3,439 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0000884731-17-000052 · wf-form4_148727253657061.xml · derivative · entry 6 Bollag Daniel M · CIK 0001461612 · Sr. VP, Reg. Affairs & Quality 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,439 shares Expires not disclosed F4 · derivative.exercise_date: Pursuant to the Merger Agreement, each RSU outstanding immediately prior to the consummation of the Offer automatically and without any required action on the part of its holder shall be converted into the right to receive an amount in cash equal to $24.00 for each Share underlying the RSUs (the aggregate amount, the "RSU Payment"). Subject to the terms of the award agreement, the RSU Payment will generally be payable (without any crediting of interest for the period from the consummation of the Offer through the date of payment) in three annual installments with each such installment paid on the date that the RSUs corresponding to such installment would have otherwise vested in accordance with the terms of the award, less any required withholding taxes. F4 · derivative.expiration_date: Pursuant to the Merger Agreement, each RSU outstanding immediately prior to the consummation of the Offer automatically and without any required action on the part of its holder shall be converted into the right to receive an amount in cash equal to $24.00 for each Share underlying the RSUs (the aggregate amount, the "RSU Payment"). Subject to the terms of the award agreement, the RSU Payment will generally be payable (without any crediting of interest for the period from the consummation of the Offer through the date of payment) in three annual installments with each such installment paid on the date that the RSUs corresponding to such installment would have otherwise vested in accordance with the terms of the award, less any required withholding taxes. Read SEC document |
| February 16, 2017 Filed Feb 16, 2017 14:15 UTC | ARIAD PHARMACEUTICALS INC ARIA · Entity 134569 | Disposition to issuerRestricted Stock Units · Derivative | 52,666 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0000884731-17-000052 · wf-form4_148727253657061.xml · derivative · entry 5 Bollag Daniel M · CIK 0001461612 · Sr. VP, Reg. Affairs & Quality 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 52,666 shares Expires not disclosed F3 · derivative.exercise_date: Each restricted stock unit ("RSU") represents a right to receive one Share. Pursuant to the Merger Agreement, each RSU outstanding immediately prior to the consummation of the Offer automatically and without any required action on the part of its holder became fully vested and was converted immediately prior to, and contingent upon, the consummation of the Offer into a vested right to receive a lump-sum cash payment in an amount equal to $24.00 for each Share underlying the RSU, less any required withholding taxes. F3 · derivative.expiration_date: Each restricted stock unit ("RSU") represents a right to receive one Share. Pursuant to the Merger Agreement, each RSU outstanding immediately prior to the consummation of the Offer automatically and without any required action on the part of its holder became fully vested and was converted immediately prior to, and contingent upon, the consummation of the Offer into a vested right to receive a lump-sum cash payment in an amount equal to $24.00 for each Share underlying the RSU, less any required withholding taxes. Read SEC document |
| February 16, 2017 Filed Feb 16, 2017 14:15 UTC | ARIAD PHARMACEUTICALS INC ARIA · Entity 134569 | Disposition to issuerEmployee Stock Option (Right to Buy) · Derivative | 60,000 | $0.00 Strike: $6.51 | $0.00 |
DisclosureSEC source: 0000884731-17-000052 · wf-form4_148727253657061.xml · derivative · entry 4 Bollag Daniel M · CIK 0001461612 · Sr. VP, Reg. Affairs & Quality 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 60,000 shares Expires not disclosed F2 · derivative.exercise_date: Pursuant to the Merger Agreement, each option outstanding immediately prior to the consummation of the tender offer by Takeda and Purchaser to acquire all the outstanding Shares for $24.00 in cash (the "Offer"), whether vested or unvested, automatically became fully vested and was canceled as of immediately prior to, and contingent upon, the consummation of the Offer in exchange for the right to receive a lump-sum cash payment in the amount of the Option Consideration, if any, less any required withholding taxes, with respect to such Option. "Option Consideration" means, with respect to any Option, an amount equal to the product of (i) the number of Shares issuable under such Option multiplied by (ii) the excess of (x) $24.00 over (y) the exercise price payable in respect of each Share issuable under such Option; provided, however, that the Option Consideration for each Option with an exercise price equal to or greater than $24.00 shall be $0. F2 · derivative.expiration_date: Pursuant to the Merger Agreement, each option outstanding immediately prior to the consummation of the tender offer by Takeda and Purchaser to acquire all the outstanding Shares for $24.00 in cash (the "Offer"), whether vested or unvested, automatically became fully vested and was canceled as of immediately prior to, and contingent upon, the consummation of the Offer in exchange for the right to receive a lump-sum cash payment in the amount of the Option Consideration, if any, less any required withholding taxes, with respect to such Option. "Option Consideration" means, with respect to any Option, an amount equal to the product of (i) the number of Shares issuable under such Option multiplied by (ii) the excess of (x) $24.00 over (y) the exercise price payable in respect of each Share issuable under such Option; provided, however, that the Option Consideration for each Option with an exercise price equal to or greater than $24.00 shall be $0. Read SEC document |
| February 16, 2017 Filed Feb 16, 2017 14:15 UTC | ARIAD PHARMACEUTICALS INC ARIA · Entity 134569 | Disposition to issuerEmployee Stock Option (Right to Buy) · Derivative | 48,000 | $0.00 Strike: $20.89 | $0.00 |
DisclosureSEC source: 0000884731-17-000052 · wf-form4_148727253657061.xml · derivative · entry 3 Bollag Daniel M · CIK 0001461612 · Sr. VP, Reg. Affairs & Quality 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 48,000 shares Expires not disclosed F2 · derivative.exercise_date: Pursuant to the Merger Agreement, each option outstanding immediately prior to the consummation of the tender offer by Takeda and Purchaser to acquire all the outstanding Shares for $24.00 in cash (the "Offer"), whether vested or unvested, automatically became fully vested and was canceled as of immediately prior to, and contingent upon, the consummation of the Offer in exchange for the right to receive a lump-sum cash payment in the amount of the Option Consideration, if any, less any required withholding taxes, with respect to such Option. "Option Consideration" means, with respect to any Option, an amount equal to the product of (i) the number of Shares issuable under such Option multiplied by (ii) the excess of (x) $24.00 over (y) the exercise price payable in respect of each Share issuable under such Option; provided, however, that the Option Consideration for each Option with an exercise price equal to or greater than $24.00 shall be $0. F2 · derivative.expiration_date: Pursuant to the Merger Agreement, each option outstanding immediately prior to the consummation of the tender offer by Takeda and Purchaser to acquire all the outstanding Shares for $24.00 in cash (the "Offer"), whether vested or unvested, automatically became fully vested and was canceled as of immediately prior to, and contingent upon, the consummation of the Offer in exchange for the right to receive a lump-sum cash payment in the amount of the Option Consideration, if any, less any required withholding taxes, with respect to such Option. "Option Consideration" means, with respect to any Option, an amount equal to the product of (i) the number of Shares issuable under such Option multiplied by (ii) the excess of (x) $24.00 over (y) the exercise price payable in respect of each Share issuable under such Option; provided, however, that the Option Consideration for each Option with an exercise price equal to or greater than $24.00 shall be $0. Read SEC document |
| February 16, 2017 Filed Feb 16, 2017 14:15 UTC | ARIAD PHARMACEUTICALS INC ARIA · Entity 134569 | Disposition to issuerEmployee Stock Option (Right to Buy) · Derivative | 38,000 | $0.00 Strike: $15.05 | $0.00 |
DisclosureSEC source: 0000884731-17-000052 · wf-form4_148727253657061.xml · derivative · entry 2 Bollag Daniel M · CIK 0001461612 · Sr. VP, Reg. Affairs & Quality 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 38,000 shares Expires not disclosed F2 · derivative.exercise_date: Pursuant to the Merger Agreement, each option outstanding immediately prior to the consummation of the tender offer by Takeda and Purchaser to acquire all the outstanding Shares for $24.00 in cash (the "Offer"), whether vested or unvested, automatically became fully vested and was canceled as of immediately prior to, and contingent upon, the consummation of the Offer in exchange for the right to receive a lump-sum cash payment in the amount of the Option Consideration, if any, less any required withholding taxes, with respect to such Option. "Option Consideration" means, with respect to any Option, an amount equal to the product of (i) the number of Shares issuable under such Option multiplied by (ii) the excess of (x) $24.00 over (y) the exercise price payable in respect of each Share issuable under such Option; provided, however, that the Option Consideration for each Option with an exercise price equal to or greater than $24.00 shall be $0. F2 · derivative.expiration_date: Pursuant to the Merger Agreement, each option outstanding immediately prior to the consummation of the tender offer by Takeda and Purchaser to acquire all the outstanding Shares for $24.00 in cash (the "Offer"), whether vested or unvested, automatically became fully vested and was canceled as of immediately prior to, and contingent upon, the consummation of the Offer in exchange for the right to receive a lump-sum cash payment in the amount of the Option Consideration, if any, less any required withholding taxes, with respect to such Option. "Option Consideration" means, with respect to any Option, an amount equal to the product of (i) the number of Shares issuable under such Option multiplied by (ii) the excess of (x) $24.00 over (y) the exercise price payable in respect of each Share issuable under such Option; provided, however, that the Option Consideration for each Option with an exercise price equal to or greater than $24.00 shall be $0. Read SEC document |
| February 16, 2017 Filed Feb 16, 2017 14:15 UTC | ARIAD PHARMACEUTICALS INC ARIA · Entity 134569 | Disposition to issuerCommon Stock | 126,352 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000884731-17-000052 · wf-form4_148727253657061.xml · nonDerivative · entry 1 Bollag Daniel M · CIK 0001461612 · Sr. VP, Reg. Affairs & Quality 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · price: Pursuant to the Agreement and Plan of Merger, dated as of January 8, 2017 (the "Merger Agreement"), between the Company, Takeda Pharmaceutical Company Limited ("Takeda") and Kiku Merger Co., Inc. ("Purchaser"), on February 16, 2017, Merger Sub was merged with and into the Company, with the Company continuing as the surviving corporation and a wholly owned subsidiary of Parent (the "Merger"). Pursuant to the Merger Agreement, at the effective time of the Merger, each share of common stock, par value $0.001 per share, of the Company (each, a "Share") was converted into the right to receive $24.00 in cash. Read SEC document |
| February 06, 2017 Filed Feb 7, 2017 16:58 UTC | ARIAD PHARMACEUTICALS INC ARIA · Entity 134569 | GrantRestricted Stock Units · Derivative | 3,439 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0000884731-17-000029 · wf-form4_148650470093986.xml · derivative · entry 1 Bollag Daniel M · CIK 0001461612 · Sr. VP, Reg. Affairs & Quality 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,439 Underlying: Common Stock · 3,439 shares Expires not disclosed F1 · derivative.exercise_date: The Restricted Stock Units ("RSUs") vest as to approximately one-third of the shares underlying the RSUs on each anniversary of the grant date; provided, however, that, subject to and effective upon the consummation of the transactions contemplated by that certain Agreement and Plan of Merger between ARIAD, Takeda Pharmaceutical Company Limited, and Kiku Merger Co., Inc., dated January 8, 2017, the RSUs shall be converted into the right to receive a cash amount equal to $24.00 for each share of common stock underlying the RSUs, payable in three annual installments on each anniversary of the grant date, subject to the terms of the award. F2 · derivative.expiration_date: N/A Read SEC document |
| January 31, 2017 Filed Feb 2, 2017 16:42 UTC | ARIAD PHARMACEUTICALS INC ARIA · Entity 134569 | Exercise / conversionRestricted Stock Units · Derivative | 29,333 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0000884731-17-000018 · wf-form4_148607172612766.xml · derivative · entry 3 Bollag Daniel M · CIK 0001461612 · Sr. VP, Reg. Affairs & Quality 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 29,333 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Shares were acquired upon the vesting of a Restricted Stock Unit previously granted on January 31, 2014. F4 · derivative.exercise_date: Restricted Stock Units vest as approximately to one-third of the award on each of January 31, 2015, January 31, 2016 and January 31, 2017. F5 · derivative.expiration_date: N/A Read SEC document |
| January 31, 2017 Filed Feb 2, 2017 16:42 UTC | ARIAD PHARMACEUTICALS INC ARIA · Entity 134569 | Tax withholdingCommon Stock | 14,667 | $23.81 | $349,293.14 |
DisclosureSEC source: 0000884731-17-000018 · wf-form4_148607172612766.xml · nonDerivative · entry 2 Bollag Daniel M · CIK 0001461612 · Sr. VP, Reg. Affairs & Quality 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 126,352 F2 · kind: Shares were sold to satisfy the Company's tax withholding obligations pursuant to a Rule 10b5-1 plan adopted on June 15, 2016. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $23.795 to $23.83, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| January 31, 2017 Filed Feb 2, 2017 16:42 UTC | ARIAD PHARMACEUTICALS INC ARIA · Entity 134569 | Exercise / conversionCommon Stock | 29,333 | $0.00 | $0.00 |
DisclosureSEC source: 0000884731-17-000018 · wf-form4_148607172612766.xml · nonDerivative · entry 1 Bollag Daniel M · CIK 0001461612 · Sr. VP, Reg. Affairs & Quality 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 141,019 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Shares were acquired upon the vesting of a Restricted Stock Unit previously granted on January 31, 2014. Read SEC document |
| January 09, 2017 Filed Jan 10, 2017 18:17 UTC | ARIAD PHARMACEUTICALS INC ARIA · Entity 134569 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 32,000 | $0.00 Strike: $7.82 | $0.00 |
DisclosureSEC source: 0000884731-17-000002 · wf-form4_148409024894416.xml · derivative · entry 3 Bollag Daniel M · CIK 0001461612 · Sr. VP, Reg. Affairs & Quality 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 32,000 shares Expires 2021-04-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 09, 2017 Filed Jan 10, 2017 18:17 UTC | ARIAD PHARMACEUTICALS INC ARIA · Entity 134569 | SaleCommon Stock | 32,000 | $23.78 | $760,960.00 |
DisclosureSEC source: 0000884731-17-000002 · wf-form4_148409024894416.xml · nonDerivative · entry 2 Bollag Daniel M · CIK 0001461612 · Sr. VP, Reg. Affairs & Quality 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 129,404 F2 · kind: Shares were sold pursuant to a Rule 10b5-1 trading plan dated June 15, 2016 Read SEC document |
| January 09, 2017 Filed Jan 10, 2017 18:17 UTC | ARIAD PHARMACEUTICALS INC ARIA · Entity 134569 | Exercise / conversionCommon Stock | 32,000 | $7.82 | $250,240.00 |
DisclosureSEC source: 0000884731-17-000002 · wf-form4_148409024894416.xml · nonDerivative · entry 1 Bollag Daniel M · CIK 0001461612 · Sr. VP, Reg. Affairs & Quality 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 161,404 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Shares were acquired from exercise of an outstanding stock option pursuant to a Rule 10b5-1 trading plan adopted on June 15, 2016 Read SEC document |
| October 03, 2016 Filed Oct 5, 2016 16:17 UTC | ARIAD PHARMACEUTICALS INC ARIA · Entity 134569 | SaleCommon Stock | 47,384 | $13.46 | $637,812.33 |
DisclosureSEC source: 0000884731-16-000109 · wf-form4_147569866608040.xml · nonDerivative · entry 1 Bollag Daniel M · CIK 0001461612 · Sr. VP, Reg. Affairs & Quality 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 129,404 F1 · kind: Shares were sold pursuant to a Rule 10b5-1 trading plan dated June 15, 2016 F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $13.33 to $13.65 inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer,or the staff of the Securities and Exchange Commission, upon request, full information regarding the shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| September 26, 2016 Filed Sep 28, 2016 16:20 UTC | ARIAD PHARMACEUTICALS INC ARIA · Entity 134569 | Exercise / conversionPerformance stock unit · Derivative | 10,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000884731-16-000107 · wf-form4_147509400503944.xml · derivative · entry 2 Bollag Daniel M · CIK 0001461612 · Sr. VP, Reg. Affairs & Quality 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 10,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each performance stock unit represents a right to receive done share of ARIAD common stock F3 · derivative.exercise_date: The performance stock units vest as to 50% of the award on 9/24/15 and 50% of the award on 9/26/2016. F3 · derivative.expiration_date: The performance stock units vest as to 50% of the award on 9/24/15 and 50% of the award on 9/26/2016. Read SEC document |
| September 26, 2016 Filed Sep 28, 2016 16:20 UTC | ARIAD PHARMACEUTICALS INC ARIA · Entity 134569 | Exercise / conversionCommon Stock | 10,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000884731-16-000107 · wf-form4_147509400503944.xml · nonDerivative · entry 1 Bollag Daniel M · CIK 0001461612 · Sr. VP, Reg. Affairs & Quality 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 176,788 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Shares were acquired upon vesting of performance stock units awarded on March 19, 2013. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.